Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) shares, rose in value, with the stock price down by -5.07% to the previous day’s close as strong demand from buyers drove the stock to $532.50.
Actively observing the price movement in the recent trading, the stock is buoying the session at $560.93. The PE ratio was 13.55 over 12-month period. Referring to stock’s 52-week performance, its high was $1211.20, and the low was $525.99. On the whole, REGN has fluctuated by -4.37% over the past month.
With the market capitalization of Regeneron Pharmaceuticals, Inc currently standing at about $57.49 billion, investors are eagerly awaiting this quarter’s results, scheduled for in June. The company’s Forward Dividend Ratio is 0.88, with its dividend yield at 0.17%.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that REGN’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 7.53, with the price of REGN currently trading nearly -7.46% and -14.60% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 36.06, while the 7-day volatility ratio is showing 3.58% which for the 30-day chart, stands at 4.41%. Furthermore, Regeneron Pharmaceuticals, Inc (REGN)’s beta value is 0.39, and its average true range (ATR) is 26.43.
A comparison of Regeneron Pharmaceuticals, Inc (REGN) with its peers suggests the former has fared considerably weaker in the market. REGN showed an intraday change of -5.07% in today’s session so far, and over the past year, it shrunk by -44.45%%.
Data on historical trading for Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) indicates that the trading volumes over the past 3 months, they’ve averaged 1.06 million. According to company’s latest data on outstanding shares, there are 106.40 million shares outstanding.
Nearly 3.61% of Regeneron Pharmaceuticals, Inc’s shares belong to company insiders and institutional investors own 88.61% of the company’s shares. The stock has fallen by -25.25% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the REGN stock heading into the next quarter.
